Table 1 Results of preemptive and... | American Society of Hematology

Table 1

Results of preemptive and salvage DLI, respectively, for patients with myelofibrosis

Patient no.	Sex	Age, y	Donor	Reason for DLI	No. of DLIs	GVHD	Other complications	Best response	Further treatment	Actual status	DLI dose, per kg BW
1	m	51	MUD	Relapse	2	none	none	mCR	none	mCRat 18 mo+	1-6 × 10⁶ CD3⁺
2	m	32	MUD	Relapse	3	none	none	mCR	none	mCR 3 mo	5 × 10⁵-1 × 10⁷ CD3⁺
3	f	51	MUD	Relapse	4	acute (grade III), chronic (extensive)	aplasia	CR*	none	CR 29 mo+	1 × 10⁶-1.3 × 10⁸ CD3⁺
4	m	55	MUD	MRD	1	none	none	mCR	none	mCR 31 mo+	1 × 10⁶ CD3⁺
5	m	49	MUD	Relapse	4	none	none	SD	2nd SCT	mCR 34 mo+	1 × 10⁶-4 × 10⁷ CD3⁺
6	m	59	MUD	Relapse	2	none	none	SD	2nd SCT	died (relapse) 18 mo after 2nd SCT	1 × 10⁶ CD3⁺
7	f	34	MUD	MRD	1	none	none	mCR	none	mCR 6 mo+	1 × 10⁶ CD4⁺
8	f	63	MUD	Relapse	1	none	none	SD	2nd SCT	CR† 19 mo after 2nd SCT	1 × 10⁶ CD3⁺
9a (9b)	m	54	REL	MRD	1 (3)	chronic (limited)	none	mCR	none	mCR‡ 8 mo+	1 × 10⁶ CD3⁺;1 × 10⁶-5 × 10⁶ CD3⁺
10	m	54	MUD	Relapse	3	none	none	PD	2nd SCT	mCR 4 mo+ after 2nd SCT	1 × 10⁶-9 × 10⁶ CD3⁺
11	f	44	REL	MRD	1	none	none	mCR	none	mCR 10 mo+	5 × 10⁶ CD3⁺
12	m	47	MUD	MRD	1	none	none	mCR	none	mCR 5 mo+	5 × 10⁵ CD3⁺
13	f	48	REL	Relapse	3	none	none	Ci	2nd SCT	mCR 3 mo+	1 × 10⁶-1 × 10⁸ CD3⁺
14	f	53	MUD	MRD	2	none	none	mCR	none	mCR 18 mo+	1 × 10⁶ CD3⁺
15	f	60	REL	Relapse	1	acute (III)	aplasia	mCR	none	mCR 6 mo+	5 × 10⁶ CD4⁺
16	m	50	REL	MRD	1	none	none	mCR	none	mCR 2 mo+	3 × 10⁶ CD3⁺
17	m	63	MUD	MRD	1	acute (grade I), chronic	none	mCR	none	mCR 7 mo+	5 × 10⁵ CD3⁺

Patient no.	Sex	Age, y	Donor	Reason for DLI	No. of DLIs	GVHD	Other complications	Best response	Further treatment	Actual status	DLI dose, per kg BW
1	m	51	MUD	Relapse	2	none	none	mCR	none	mCRat 18 mo+	1-6 × 10⁶ CD3⁺
2	m	32	MUD	Relapse	3	none	none	mCR	none	mCR 3 mo	5 × 10⁵-1 × 10⁷ CD3⁺
3	f	51	MUD	Relapse	4	acute (grade III), chronic (extensive)	aplasia	CR*	none	CR 29 mo+	1 × 10⁶-1.3 × 10⁸ CD3⁺
4	m	55	MUD	MRD	1	none	none	mCR	none	mCR 31 mo+	1 × 10⁶ CD3⁺
5	m	49	MUD	Relapse	4	none	none	SD	2nd SCT	mCR 34 mo+	1 × 10⁶-4 × 10⁷ CD3⁺
6	m	59	MUD	Relapse	2	none	none	SD	2nd SCT	died (relapse) 18 mo after 2nd SCT	1 × 10⁶ CD3⁺
7	f	34	MUD	MRD	1	none	none	mCR	none	mCR 6 mo+	1 × 10⁶ CD4⁺
8	f	63	MUD	Relapse	1	none	none	SD	2nd SCT	CR† 19 mo after 2nd SCT	1 × 10⁶ CD3⁺
9a (9b)	m	54	REL	MRD	1 (3)	chronic (limited)	none	mCR	none	mCR‡ 8 mo+	1 × 10⁶ CD3⁺;1 × 10⁶-5 × 10⁶ CD3⁺
10	m	54	MUD	Relapse	3	none	none	PD	2nd SCT	mCR 4 mo+ after 2nd SCT	1 × 10⁶-9 × 10⁶ CD3⁺
11	f	44	REL	MRD	1	none	none	mCR	none	mCR 10 mo+	5 × 10⁶ CD3⁺
12	m	47	MUD	MRD	1	none	none	mCR	none	mCR 5 mo+	5 × 10⁵ CD3⁺
13	f	48	REL	Relapse	3	none	none	Ci	2nd SCT	mCR 3 mo+	1 × 10⁶-1 × 10⁸ CD3⁺
14	f	53	MUD	MRD	2	none	none	mCR	none	mCR 18 mo+	1 × 10⁶ CD3⁺
15	f	60	REL	Relapse	1	acute (III)	aplasia	mCR	none	mCR 6 mo+	5 × 10⁶ CD4⁺
16	m	50	REL	MRD	1	none	none	mCR	none	mCR 2 mo+	3 × 10⁶ CD3⁺
17	m	63	MUD	MRD	1	acute (grade I), chronic	none	mCR	none	mCR 7 mo+	5 × 10⁵ CD3⁺

CR indicates complete remission; mCR, molecular complete remission; Ci, clinical improvement; SD, stable disease; PD, progressive disease; REL, relative donor; MUD, matched unrelated donor; DLI, donor-lymphocyte infusion; GVHD, graft-versus-host disease; SCT, stem cell transplantation; and MRD, molecular residual disease.

No molecular marker; complete remission according to IWG consensus creiteria and 100% donor chimerism with quantitative PCR.

†

Clinical CR on molecular basis, residual disease.

‡

After first DLI.

View Large

This Feature Is Available To Subscribers Only